249 related articles for article (PubMed ID: 21402610)
1. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.
Nichols HB; Berrington de González A; Lacey JV; Rosenberg PS; Anderson WF
J Clin Oncol; 2011 Apr; 29(12):1564-9. PubMed ID: 21402610
[TBL] [Abstract][Full Text] [Related]
2. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
5. Declining second primary ovarian cancer after first primary breast cancer.
Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
[TBL] [Abstract][Full Text] [Related]
6. Second primary breast cancer occurrence according to hormone receptor status.
Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
[TBL] [Abstract][Full Text] [Related]
7. Incidence of metachronous contralateral breast cancer in Denmark 1978-2009.
Rasmussen CB; Kjær SK; Ejlertsen B; Andersson M; Jensen MB; Christensen J; Langballe R; Mellemkjær L
Int J Epidemiol; 2014 Dec; 43(6):1855-64. PubMed ID: 25326461
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
9. Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004-2013): Amassing data from independent Western populations provide etiologic clues.
Mullooly M; Murphy J; Gierach GL; Walsh PM; Deady S; Barron TI; Sherman ME; Rosenberg PS; Anderson WF
Eur J Cancer; 2017 Nov; 86():326-333. PubMed ID: 29073583
[TBL] [Abstract][Full Text] [Related]
10. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
11. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
Mezencev R; Švajdler M
Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
[TBL] [Abstract][Full Text] [Related]
12. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.
Gao X; Fisher SG; Emami B
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1038-45. PubMed ID: 12829139
[TBL] [Abstract][Full Text] [Related]
13. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
[TBL] [Abstract][Full Text] [Related]
14. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
[TBL] [Abstract][Full Text] [Related]
15. Incidence of breast cancer in the United States: current and future trends.
Anderson WF; Katki HA; Rosenberg PS
J Natl Cancer Inst; 2011 Sep; 103(18):1397-402. PubMed ID: 21753181
[TBL] [Abstract][Full Text] [Related]
16. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
[TBL] [Abstract][Full Text] [Related]
17. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
Neta G; Anderson WF; Gilbert E; Berrington A
Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
[TBL] [Abstract][Full Text] [Related]
18. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
Jemal A; Ward E; Thun MJ
Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer.
Sandberg ME; Hartman M; Klevebring D; Eloranta S; Ploner A; Hall P; Czene K
Breast Cancer Res Treat; 2012 Jul; 134(2):793-800. PubMed ID: 22622811
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for contralateral breast cancer in Chennai (Madras), India.
Gajalakshmi CK; Shanta V; Hakama M
Int J Epidemiol; 1998 Oct; 27(5):743-50. PubMed ID: 9839728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]